It is ongoing that a phase II/III study of PM8002(a bispecific antibody targeting PD-L1 and VEGF) in combination with chemotherapy in patients with EGFR-mutant advanced NSCLC who have failed to EGFR-TKI treatment (NCT05756972). This evidence concerns the gene EGFR and non-small cell lung carcinoma.